Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Title: Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes

Authors: *Elena E. Sereda, Elena. S. Kolegova, Gelena V. Kakurina, Dmitriy A. Korshunov, Evgenia A. Sidenko, Artem V. Doroshenko, Elena M. Slonimskaya, Irina V. Kondakova*

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Page 8, line 187-194 (Materials and Methods section/Antibodies and reagents paragraph)	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	not provided	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	not provided	

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	not provided	
Animal observed in or captured from the field: Provide species, sex and age where possible	not provided	
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	not provided	

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	not provided	
Microbes: provide species and strain, unique accession number if available, and source	not provided	

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 8, line 178-181 (Materials and Methods section/Human Samples paragraph); Page 23, line 506-511 (Footnote/ Ethics approval and consent to participate)	
Provide statement confirming informed consent obtained from study participants.	Page 8, line 181 (Materials and Methods section/Human Samples paragraph) and Page 23, line 510-511 (Footnote section/ consent to participate paragraph)	
Report on age and sex for all study participants.	All patients in this breast cancer study were female.	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	not provided	

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	Materials and Methods Section	

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.	Materials and Methods Section	
Sample size determination	Page 6, Materials and Methods Section	
Randomisation	Pages 6-8, Materials and Methods Section	
Blinding		
Inclusion/exclusion criteria	Pages 6-8, Materials and Methods Section	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory		
Define whether data describe technical or biological replicates		

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Local Ethics Committee of the Cancer Research Institute of Tomsk National Research Medical Center (protocol №2 from 4 April 2017). Page 8, line 178-181 (Materials and Methods section/Human Samples paragraph); Page 23, line 506-511 (Footnote/ Ethics approval and consent to participate)	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	not provided	
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	not provided	

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for profit sectors. Page 24, line 519-520 (Footnote Section / Funding paragraph)	

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Pages 6-8, Materials and Methods Section	

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Pages 10-11, Materials and Methods Section	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Data underlying the findings described in this manuscript may be obtained upon request as long as the request is in keeping with the terms under which the Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences received the data. Samples of the compounds are not available from the authors. page 23: footnote section/line 512-516	
If data are publicly available, provide accession number in repository or DOI or URL.	not provided	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	not provided	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	Not provided	
State whether the code or software is available.	not provided	
If code is publicly available, provide accession number in repository, or DOI or URL.	not provided	

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	We present the following article in accordance with the MDAR reporting checklist. (page 6: Introduction section/ line 144-145 and page 23: footnote section/line 502-505)	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/tbcr-22-22